Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergopharma Subcutaneous Allergen Immunotherapy
- Development stage
- Unknown
- Lead developer
- DermaPharm
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Allergopharma Subcutaneous Allergen Immunotherapy (SCIT) refers to a range of therapeutic products developed by Allergopharma (a subsidiary of Dermapharm) for the treatment of IgE-mediated allergic diseases. These products consist of specific allergen extracts, such as grass pollen, house dust mites, and birch pollen, which are adsorbed to aluminum hydroxide to create a depot effect. The treatment involves the repeated subcutaneous administration of these extracts to gradually induce immune tolerance and desensitize the patient's immune system. The product line includes **Novo-Helisen Depot**, which contains unmodified allergen extracts, and **Allergovit**, which consists of modified allergoids (hypoallergenic, high-dose preparations). These therapies are primarily indicated for allergic rhinitis, seasonal allergies, house dust mite allergy, and allergic asthma, aiming to modify the underlying allergic immune response rather than just treating symptoms.
- Brand names
- Novo-Helisen DepotAllergovit
- Other names
- subcutaneous allergen immunotherapySCITallergen extractsallergoidssubcutaneous preparations
02
Targets
IgE (Immunoglobulin E)sIgG4 (Allergen-specific immunoglobulin G4)MHC II (Major histocompatibility complex class II receptor)Phleum pratense allergens
Beyond the preview
Go deeper on Allergopharma Subcutaneous Allergen Immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allergopharma Subcutaneous Allergen Immunotherapy.